Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016

Yuki Shimada1, Akihiko Ozaki2,3, Hiroaki Saito4, Toyoaki Sawano5, Tetsuya Tanimoto2
1Department of Neurosurgery, Minamisoma Municipal General Hospital, Minamisoma, Fukushima, Japan
2Medical Governance Research Institute, Tokyo, Japan
3Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan
4Department of Gastroenterology, Sendai Kousei Hospital, Sendai, Miyagi, Japan
5Department of Surgery, Minamisoma Municipal General Hospital, Minamisoma, Fukushima, Japan

Tóm tắt

AbstractIntroductionFinancial relationships between pharmaceutical companies and dementia clinical practice guideline (CPG) authors are possibly biasing the recommendations in Japan. This study aimed to reveal characteristics and distribution of pharmaceutical payments made to Japanese dementia CPG authors and an extent of the transparency in the conflicts of interest disclosure among them.MethodsWe retrospectively retrieved the publicly available data on payment to all the authors in the dementia CPGs by major pharmaceutical companies in Japan in 2016.ResultsThe total and mean payment values from pharmaceutical companies were $880,061 and $14,427, respectively. Of the 61 authors, 49 (80.3%) physicians received at least one payment. Financial relationships of the individual authors were not disclosed in the CPGs.DiscussionPharmaceutical companies with antidementia drugs had strong financial relationships with the CPG authors. To guarantee fairness in their relationships, it is imperative to establish a framework to disclose the corporate financial conflicts of interest.

Tài liệu tham khảo

10.1001/jama.287.5.612 Prince M., 2015, World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends 10.1001/jamaoncol.2016.2710 10.1001/jamadermatol.2017.3109 10.1001/jamainternmed.2018.4730 10.1016/j.jalz.2016.07.150